Decibel Therapeutics, Inc. (DBTX)
| Market Cap | 356.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.67M |
| Shares Out | 24.28M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $14.68 |
| Previous Close | $17.67 |
| Change ($) | -2.99 |
| Change (%) | -16.92% |
| Day's Open | 17.85 |
| Day's Range | 13.28 - 17.85 |
| Day's Volume | 261,771 |
| 52-Week Range | 13.28 - 24.39 |
Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at ...
Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Rese...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented t...
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to resto...
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and...
Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.
Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.
Decibel Therapeutics, a Phase 1 biotech developing treatments for hearing and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
Decibel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
...Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M.
BOSTON--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announc...
About DBTX
Decibel Therapeutics, a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disor... [Read more...]
| Industry Biotechnology | IPO Date Feb 12, 2021 |
| CEO Laurence Reid, Ph.D. | Employees 37 |
| Stock Exchange NASDAQ | Ticker Symbol DBTX |